FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313478654> ?p ?o ?g. }

• W4313478654 endingPage "100402" @default.
• W4313478654 startingPage "100402" @default.
• W4313478654 abstract "The current COVID-19 pandemic from the human pathogenic virus SARS-CoV-2 has resulted in a major health hazard globally. The morbidity and transmission modality of this disease are severe and uncontrollable. As no effective clinical drugs are available for treatment of COVID-19 infection till to date and only vaccination is used as prophylaxis and its efficacy is restricted due to emergent of new variants of SARS-CoV-2, there is an urgent need for effective drugs for its treatment.The aim of this review was to provide a detailed analysis of anti-SARS-CoV-2 efficacy of (-)-epigallocatechin-3-O-gallate (EGCG), a major catechin constituent of green tea (Camellia sinensis (L.) Kuntze) beverage to highlight the scope of EGCG in clinical medicine as both prophylaxis and treatment of present COVID-19 infection. In addition, the factors related to poor oral bioavailabilty of EGCG was also analysed for a suggestion for future research in this direction.We collected the published articles related to anti-SARS-CoV-2 activity of EGCG against the original strain (Wuhan type) and its newly emerged variants of SARS-CoV-2 virus.A systematic search on the published literature was conducted in various databases including Google Scholar, PubMed, Science Direct and Scopus to collect the relevant literature.The findings of this search demonstrate that EGCG shows potent antiviral activity against SARS-CoV-2 virus by preventing viral entry and replication in host cells in vitro models. The studies on the molecular mechanisms of EGCG in inhibition of SARS-CoV-2 infection in host cells reveal that EGCG blocks the entry of the virus particles by interaction with the receptor binding domain (RBD) of viral spike (S) protein to host cell surface receptor protease angiotensin-converting enzyme 2 (ACE2) as well as suppression of the expressions of host proteases, ACE2, TMPRSS2 and GRP78, required for viral entry, by Nrf2 activation in host cells. Moreover, EGCG inhibits the activities of SARS-CoV-2 main protease (Mpro), papain-like protease (PLpro), endoribonuclease Nsp15 in vitro models and of RNA-dependent RNA polymerase (RdRp) in molecular docking model for suppression of viral replication. In addition, EGCG significantly inhibits viral inflammatory cytokine production by stimulating Nrf2- dependent host immune response in virus-infected cells. EGCG significantly reduces the elevated levels of HMGB1, a biomarker of sepsis, lung fibrosis and thrombotic complications in viral infections. EGCG potentially inhibits the infection of original (Wuhan type) strain of SARS-CoV-2 and other newly emerged variants as well as the infections of SARS-CoV-2 virus spike-protein of WT and its mutants-mediated pseudotyped viruses . EGCG shows maximum inhibitory effect against SARS-CoV-2 infection when the host cells are pre-incubated with the drug prior to viral infection. A sorbitol/lecithin-based throat spray containing concentrated green tea extract rich in EGCG content significantly reduces SARS-CoV-2 infectivity in oral mucosa. Several factors including degradation in gastrointestinal environment, low absorption in small intestine and extensive metabolism of EGCG are responsible for its poor bioavailability in humans. Pharmacokinetic and metabolism studies of EGCG in humans reveal poor bioavailability of EGCG in human plasma and EGCG-4-sulfate is its major metabolite. The concentration of EGCG-4-sulfate in human plasma is almost equivalent to that of free EGCG (Cmax 177.9 vs 233.5 nmol/L). These findings suggest that inhibition of sulfation of EGCG is a crucial factor for improvement of its bioavailability. In vitro study on the mechanism of EGCG sulfonation indicates that sulfotransferases, SULT1A1 and SULT1A3 are responsible for sulfonation in human liver and small intestine, respectively. Some attempts including structural modifications, and nanoformulations of EGCG and addition of nutrients with EGCG have been made to improve the bioavailability of EGCG.The findings of this study suggest that EGCG has strong antiviral activity against SARS-CoV-2 infection independent of viral strains (Wuhan type (WT), other variants) by inhibition of viral entry and replication in host cells in vitro models. EGCG may be useful in reduction of this viral load in salivary glands of COVID-19 patients, if it is applied in mouth and throat wash formulations in optimal concentrations. EGCG could be a promising candidate in the development of effective vaccine for prevention of the infections of newly emergent strains of SARS-CoV-2 virus. EGCG might be useful also as a clinical medicine for treatment of COVID-19 patients if its bioavailability in human plasma is enhanced." @default.
• W4313478654 created "2023-01-06" @default.
• W4313478654 creator A5001909736 @default.
• W4313478654 creator A5053589155 @default.
• W4313478654 creator A5073030190 @default.
• W4313478654 date "2023-02-01" @default.
• W4313478654 modified "2023-10-09" @default.
• W4313478654 title "Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-O-gallate (EGCG) in SARS-CoV-2 infection: Major interactions with host/virus proteases" @default.
• W4313478654 cites W1754406199 @default.
• W4313478654 cites W1796831866 @default.
• W4313478654 cites W1898586228 @default.
• W4313478654 cites W1920229574 @default.
• W4313478654 cites W1931422098 @default.
• W4313478654 cites W1962199957 @default.
• W4313478654 cites W1969601405 @default.
• W4313478654 cites W1973832939 @default.
• W4313478654 cites W1976536201 @default.
• W4313478654 cites W1978849306 @default.
• W4313478654 cites W1983247237 @default.
• W4313478654 cites W1984468751 @default.
• W4313478654 cites W1985938755 @default.
• W4313478654 cites W1994190235 @default.
• W4313478654 cites W1999768609 @default.
• W4313478654 cites W2000177767 @default.
• W4313478654 cites W2005533210 @default.
• W4313478654 cites W2009631807 @default.
• W4313478654 cites W2009882421 @default.
• W4313478654 cites W2013499952 @default.
• W4313478654 cites W2028305499 @default.
• W4313478654 cites W2032545175 @default.
• W4313478654 cites W2034160470 @default.
• W4313478654 cites W2046525105 @default.
• W4313478654 cites W2049742859 @default.
• W4313478654 cites W2053473486 @default.
• W4313478654 cites W2066283836 @default.
• W4313478654 cites W2067668889 @default.
• W4313478654 cites W2070701021 @default.
• W4313478654 cites W2070926162 @default.
• W4313478654 cites W2072351356 @default.
• W4313478654 cites W2072351681 @default.
• W4313478654 cites W2075429429 @default.
• W4313478654 cites W2080911456 @default.
• W4313478654 cites W2081145665 @default.
• W4313478654 cites W2083977136 @default.
• W4313478654 cites W2088155787 @default.
• W4313478654 cites W2094602650 @default.
• W4313478654 cites W2100593398 @default.
• W4313478654 cites W2105408725 @default.
• W4313478654 cites W2109877900 @default.
• W4313478654 cites W2117912144 @default.
• W4313478654 cites W2119108696 @default.
• W4313478654 cites W2125565767 @default.
• W4313478654 cites W2126952890 @default.
• W4313478654 cites W2135359579 @default.
• W4313478654 cites W2143526116 @default.
• W4313478654 cites W2149169850 @default.
• W4313478654 cites W2151605986 @default.
• W4313478654 cites W2162854127 @default.
• W4313478654 cites W2292343120 @default.
• W4313478654 cites W2536155968 @default.
• W4313478654 cites W2646467224 @default.
• W4313478654 cites W2746375753 @default.
• W4313478654 cites W2785681703 @default.
• W4313478654 cites W2790644401 @default.
• W4313478654 cites W2804802143 @default.
• W4313478654 cites W2807913040 @default.
• W4313478654 cites W2897240874 @default.
• W4313478654 cites W2907874300 @default.
• W4313478654 cites W2913336017 @default.
• W4313478654 cites W2920901214 @default.
• W4313478654 cites W2946971820 @default.
• W4313478654 cites W2950937623 @default.
• W4313478654 cites W2965263362 @default.
• W4313478654 cites W2985222025 @default.
• W4313478654 cites W2990578183 @default.
• W4313478654 cites W2996188048 @default.
• W4313478654 cites W3002812395 @default.
• W4313478654 cites W3003464757 @default.
• W4313478654 cites W3004896487 @default.
• W4313478654 cites W3009912996 @default.
• W4313478654 cites W3011355293 @default.
• W4313478654 cites W3011416532 @default.
• W4313478654 cites W3014571869 @default.
• W4313478654 cites W3015429854 @default.
• W4313478654 cites W3018269482 @default.
• W4313478654 cites W3020358199 @default.
• W4313478654 cites W3020655115 @default.
• W4313478654 cites W3024964904 @default.
• W4313478654 cites W3033126715 @default.
• W4313478654 cites W3034034569 @default.
• W4313478654 cites W3035059950 @default.
• W4313478654 cites W3036596160 @default.
• W4313478654 cites W3037497241 @default.
• W4313478654 cites W3038198963 @default.
• W4313478654 cites W3041582510 @default.
• W4313478654 cites W3042873564 @default.
• W4313478654 cites W3042943159 @default.
• W4313478654 cites W3045750139 @default.

• next